These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 23048018

  • 21. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J, Dilla T, Arellano J.
    BMC Psychiatry; 2009 Apr 14; 9():15. PubMed ID: 19366449
    [Abstract] [Full Text] [Related]

  • 22. Neural correlates of atomoxetine improving inhibitory control and visual processing in Drug-naïve adults with attention-deficit/hyperactivity disorder.
    Fan LY, Chou TL, Gau SS.
    Hum Brain Mapp; 2017 Oct 14; 38(10):4850-4864. PubMed ID: 28657141
    [Abstract] [Full Text] [Related]

  • 23. Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis.
    Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J.
    Biol Psychiatry; 2014 Oct 15; 76(8):616-28. PubMed ID: 24314347
    [Abstract] [Full Text] [Related]

  • 24. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B, Karakaya E, Oztop DB.
    J Child Adolesc Psychopharmacol; 2015 Aug 15; 25(6):494-500. PubMed ID: 26218871
    [Abstract] [Full Text] [Related]

  • 25. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
    Shang CY, Yan CG, Lin HY, Tseng WY, Castellanos FX, Gau SS.
    Psychol Med; 2016 Nov 15; 46(15):3173-3185. PubMed ID: 27574878
    [Abstract] [Full Text] [Related]

  • 26. Dopamine transporter genotype influences the physiological response to medication in ADHD.
    Gilbert DL, Wang Z, Sallee FR, Ridel KR, Merhar S, Zhang J, Lipps TD, White C, Badreldin N, Wassermann EM.
    Brain; 2006 Aug 15; 129(Pt 8):2038-46. PubMed ID: 16760197
    [Abstract] [Full Text] [Related]

  • 27. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P, Sikirica V, Chen YJ, Curtice TG, Makin C.
    Eur J Health Econ; 2017 Sep 15; 18(7):893-904. PubMed ID: 27817164
    [Abstract] [Full Text] [Related]

  • 28. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK.
    Int J Neuropsychopharmacol; 2013 Oct 15; 16(9):1959-73. PubMed ID: 23672818
    [Abstract] [Full Text] [Related]

  • 29. Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology?
    Wehmeier PM, Dittmann RW, Banaschewski T, Schacht A.
    J Atten Disord; 2014 Feb 15; 18(2):105-16. PubMed ID: 22617861
    [Abstract] [Full Text] [Related]

  • 30. Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention.
    Rubia K, Smith AB, Halari R, Matsukura F, Mohammad M, Taylor E, Brammer MJ.
    Am J Psychiatry; 2009 Jan 15; 166(1):83-94. PubMed ID: 18829871
    [Abstract] [Full Text] [Related]

  • 31. Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
    Heinrich H, Studer P, Moll GH, Kratz O.
    JAMA Psychiatry; 2013 May 15; 70(5):545. PubMed ID: 23636880
    [No Abstract] [Full Text] [Related]

  • 32. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK, ADDUCE consortium.
    CNS Drugs; 2017 Mar 15; 31(3):199-215. PubMed ID: 28236285
    [Abstract] [Full Text] [Related]

  • 33. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P, Häge A, Coghill DR, Caballero B, Adeyi B, Anderson CS, Sikirica V, Cardo E.
    Eur Child Adolesc Psychiatry; 2016 Feb 15; 25(2):141-9. PubMed ID: 25999292
    [Abstract] [Full Text] [Related]

  • 34. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
    Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E.
    Neuropharmacology; 2009 Dec 15; 57(7-8):640-52. PubMed ID: 19715709
    [Abstract] [Full Text] [Related]

  • 35. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 15; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 36. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC, Hwang Gu SL, Lin HY, Lin YJ, Yang LK, Huang HC, Gau SS.
    J Psychopharmacol; 2016 May 15; 30(5):459-67. PubMed ID: 26905919
    [Abstract] [Full Text] [Related]

  • 37. Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder.
    An L, Cao XH, Cao QJ, Sun L, Yang L, Zou QH, Katya R, Zang YF, Wang YF.
    Neuropsychopharmacology; 2013 Jun 15; 38(7):1287-95. PubMed ID: 23340519
    [Abstract] [Full Text] [Related]

  • 38. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
    Kratz O, Studer P, Baack J, Malcherek S, Erbe K, Moll GH, Heinrich H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr 27; 37(1):81-9. PubMed ID: 22227291
    [Abstract] [Full Text] [Related]

  • 39. Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD.
    Chantiluke K, Barrett N, Giampietro V, Santosh P, Brammer M, Simmons A, Murphy DG, Rubia K.
    Psychopharmacology (Berl); 2015 Jun 27; 232(12):2071-82. PubMed ID: 25533997
    [Abstract] [Full Text] [Related]

  • 40. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May 27; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.